Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients

Abstract

A goal of HIV therapy is to sustain suppression of the plasma viral load below the detection limits of clinical assays. However, widely followed treatment guidelines diverge in their interpretation and recommended management of persistent viremia of low magnitude, reflecting the limited evidence base for this common clinical finding. Here, we review the incidence, risk factors, and potential consequences of low-level HIV viremia (LLV; defined in this review as a viremia level of 50 to 500 copies/ml) and very-low-level viremia (VLLV; defined as a viremia level of <50 copies/ml detected by clinical assays that have quantification cutoffs of <50 copies/ml). Using this framework, we discuss practical issues related to the diagnosis and management of patients experiencing persistent LLV and VLLV. Compared to viral suppression at <50 or 40 copies/ml, persistent LLV is associated with increased risk of antiretroviral drug resistance and overt virologic failure. Higher immune activation and HIV transmission may be additional undesirable consequences in this population. It is uncertain whether LLV of <200 copies/ml confers independent risks, as this level of viremia may reflect assay-dependent artifacts or biologically meaningful events during suppression. Resistance genotyping should be considered in patients with persistent LLV when feasible, and treatment should be modified if resistance is detected. There is a dearth of clinical evidence to guide management when genotyping is not feasible. Increased availability of genotypic assays for samples with viral loads of <400 copies/ml is needed.

FIG 1

Graphs of pVL over time by phase (top) and viremia level (LLV and VLLV) (bottom). Some data are from Palmer et al. (6). Persistent low-level viremia and very-low-level viremia may also occur prior to having achieved pVL suppression to <50 cpm. cART, combination antiretroviral therapy; pVL, plasma viral load; cpm, copies/ml; at phase I, the half-life (t_1/2) is 1.5 days; at phase II, the t_1/2 is 2.5 weeks; at phase III, the t_1/2 is 39 weeks. The viral blip dynamics are as described by Di Mascio et al. (108), including a 2-phase decay lasting up to 3 weeks.